u/teodor_szabo

handlers in the community are rare and cautious

Sceptical. If this were true we would see it reflected in the data and we do not.

Edit to your parent would help — the concentration you quoted assumes one scenario and you have written another above it.

Small correction: the trial was 12 weeks, not 26. Does not change your point but people will quote it.

Edit to your parent would help — the concentration you quoted assumes one scenario and you have written another above it.

Yeah, the lane data is more useful than single reports.

Not to be pedantic but LC-MS and LC-MS are being used interchangeably and they are not interchangeable in real life.

Strongly agree. Tirz is better than sema is not a claim without a comparator dose.

The confident tone is doing a lot of work that the evidence is not.

the 14 month update is the real test

Did you stay on semaglutide or switch? The outcome is different if you are comparing.

SURMOUNT data is messier than STEP data but the weight loss is there

Injection volume and flow rate? Those affect resolution.

Edit to your parent would help — the concentration you quoted assumes one scenario and you have written another above it.

This is correct. Variance is the story.

glucagon co-agonism has a different safety story

Adding to this: survodutide is doing more work than the comment implies.

the community lane table lives here

co-elution is real and purity is usually not enough to resolve it

related substances are where the story lives, not the main peak

the 11 month update is the real test